Incidence of Platelet Refractoriness in Adult Acute Leukemia Patients Receiving Prestorage Filtered Blood and Comparing With Historical Control

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

252 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-03-30

Study Completion Date

2026-03-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This research project is evaluate the incidence of platelet refractoriness in newly diagnosed acute leukemia patients receiving PFB during induction and first consolidation phase chemotherapy compared to 2 historical control groups which are patients receiving non-leukocyte depleted blood product group and leukocyte depleted blood product group and demonstrate cost-effectiveness of using blood products with filtered process to prevent clinical platelet refractoriness compare with using HLA-matched blood products after platelet refractoriness occurs

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Trial Comparing a Prophylactic With a Therapeutic Platelet Transfusion Strategy in Two Groups

NCT00521664

Myeloid Leukemia

COMPLETED PHASE3

Observational Trial of a Therapeutic Platelet Transfusion Regimen

NCT02276651

Acute Myeloid Leukemia Thrombocytopenia

TERMINATED

Hematotoxicity in Maintenance Therapy of Children With Acute Lymphoblastic Leukemia

NCT03255668

Mercaptopurine Adverse Reaction Leukemia, Lymphoblastic

COMPLETED

Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic Syndrome

NCT01311258

Acute Myeloid Leukemia Myelodysplastic Syndrome

RECRUITING

Sequential Conditioning in Haploidentical Transplantation for Refractory Acute Myeloid Leukemia

NCT03035422

Refractory Acute Myeloid Leukemia

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study the objective is to study and compare the incidence of Platelet Refractoriness. of the group that received PFB blood compared to the group that received LPPC/LPB blood in the past in patients with AML and ALL at Siriraj Hospital From the literature review, it was found that the incidence of Platelet Refractoriness of the group receiving LPPC/LPB blood in patients with AML and ALL was 46% and the incidence of Platelet Refractoriness Of the group receiving PFB blood in AML and ALL patients, it was 11% .But from the collection of blood bank data Siriraj Hospital during 2020-2021 found that the incidence of Platelet Refractoriness in AML and ALL patients who received PFB blood was approximately 27%. The researchers estimated that In this study There may be an incidence of Platelet Refractoriness. of the group receiving PFB blood in patients with AML and ALL was as high as 27%, and when determining the sample size in the group receiving LPPC/LPB blood, it was 2 times greater than the group receiving PFB blood and setting the standard value according to the table Z equal to 1.96 and The power of the test is 80% when the sample size is calculated with the formula Comparing the proportion values between two independent populations (Testing two independent proportion: Formula (without continuity correlation))

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Platelet Refractoriness in Adult Acute Leukemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Case group (PFB transfusion) Inclusion criteria

1. Newly diagnosed acute leukemia (either acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) patients underwent intensive chemotherapy
2. Age greater than 18 years
3. Participants receiving an induction chemotherapy and at least one cycle of consolidation chemotherapy

Exclusion criteria

1\. Participants with positive platelet antibody detected by SPRCA method at presentation

Withdrawal or termination criteria

1. Loss to follow up or death before completion of first consolidation chemotherapy
2. Participants receiving granulocyte infusion during time of study
3. Participants receiving SDP transfusion during time of study

No interventions assigned to this group

2

Historical control group 1 (non-leukocyte depleted blood product) Inclusion criteria

1. Newly diagnosed acute leukemia (either AML or ALL) patients underwent intensive chemotherapy during 2018-2022
2. Age greater than 18 years
3. Participants receiving an induction chemotherapy and at least one cycle of consolidation chemotherapy
4. Participants receiving only non-leukocyte depleted blood products (LPB and LPPC)

Exclusion criteria

1. Loss to follow up or death before completion of first consolidation chemotherapy
2. Participants receiving granulocyte infusion during time of study

No interventions assigned to this group

3

Historical control group 2 (leukocyte depleted blood product) Inclusion criteria

1. Newly diagnosed acute leukemia (either AML or ALL) patients underwent intensive chemotherapy during 2018-2022
2. Age greater than 18 years
3. Participants receiving an induction chemotherapy and at least one cycle of consolidation chemotherapy
4. Participants receiving leukocyte depleted blood products (PFB and SDP)

Exclusion criteria

1. Loss to follow up or death before completion of first consolidation chemotherapy during 2018-2022
2. Participants receiving granulocyte infusion during time of study
3. Participants receiving non-leukocyte depleted blood products greater than 20% of all transfused blood products during induction and first consolidation chemotherapy

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Newly diagnosed acute leukemia (either acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) patients underwent intensive chemotherapy
2. Age greater than 18 years
3. Participants receiving an induction chemotherapy and at least one cycle of consolidation chemotherapy

1. Loss to follow up or death before completion of first consolidation chemotherapy
2. Participants receiving granulocyte infusion during time of study

1. Newly diagnosed acute leukemia (either AML or ALL) patients underwent intensive chemotherapy during 2018-2022
2. Age greater than 18 years
3. Participants receiving an induction chemotherapy and at least one cycle of consolidation chemotherapy

Exclusion Criteria

1\. Participants with positive platelet antibody detected by SPRCA method at presentation

1\. Loss to follow up or death before completion of first consolidation chemotherapy during 2018-2022 2. Participants receiving granulocyte infusion during time of study 3. Participants receiving non-leukocyte depleted blood products greater than 20% of all transfused blood products during induction and first consolidation chemotherapy

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No